Limits...
Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.

Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, Sumikawa H, Johkoh T, Nakashima R, Imura Y, Mimori T, Suda T - PLoS ONE (2015)

Bottom Line: Ten-year survival rate was also significantly higher in the ARS group than in the non-ARS group (91.6% vs. 58.7%, P = 0.02).Univariate Cox hazards analysis revealed that the presence of anti-ARS antibodies was associated with better prognosis (HR = 0.34, 95% CI 0.08-0.80; P = 0.01).The presence of anti-ARS antibodies is a possible prognostic marker in patients with PM/DM-ILD.

View Article: PubMed Central - PubMed

Affiliation: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

ABSTRACT

Background: In polymyositis/dermatomyositis (PM/DM), anti-aminoacyl-tRNA synthetase (ARS) antibodies are closely associated with interstitial lung disease (ILD), a frequent pulmonary complication. However, the clinical significance of anti-ARS antibodies is not well established.

Objective: We aimed to evaluate the clinical significance of anti-ARS antibodies in PM/DM-ILD patients.

Methods: Forty-eight consecutive PM/DM-ILD patients were studied retrospectively. Anti-ARS antibodies were screened by ELISA and confirmed by RNA immunoprecipitation test. Medical records, high-resolution computed tomography images, and surgical lung biopsy specimens were compared between ARS-positive (ARS group) and ARS-negative patients (non-ARS group).

Results: Anti-ARS antibodies were detected in 23 of 48 patients (48%). Radiologically, nonspecific interstitial pneumonia (NSIP) pattern was observed more frequently in the ARS group than in the non-ARS group (73.9% vs. 40%, P = 0.02). Pathologically, NSIP was the most frequent in both groups. Ten-year survival rate was also significantly higher in the ARS group than in the non-ARS group (91.6% vs. 58.7%, P = 0.02). Univariate Cox hazards analysis revealed that the presence of anti-ARS antibodies was associated with better prognosis (HR = 0.34, 95% CI 0.08-0.80; P = 0.01).

Conclusions: The presence of anti-ARS antibodies is a possible prognostic marker in patients with PM/DM-ILD.

Show MeSH

Related in: MedlinePlus

Kaplan—Meier survival curves.The 5-year and 10-year survival rates were higher in the ARS group than in the non-ARS group (5-year: 100% vs. 69.1%; 10-year: 92.3% vs. 40.8%, P = 0.02 by log-rank test).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4366175&req=5

pone.0120313.g002: Kaplan—Meier survival curves.The 5-year and 10-year survival rates were higher in the ARS group than in the non-ARS group (5-year: 100% vs. 69.1%; 10-year: 92.3% vs. 40.8%, P = 0.02 by log-rank test).

Mentions: Twenty-two of 23 patients in the ARS group (95.7%) and 23 of 25 in the non-ARS group (92.0%) were treated for PM/DM-ILD during the observation period (Table 5). Although there was no statistically significant difference in the treatment regimen between the two groups (P = 0.22), ARS group patients exhibited a significantly higher response rate (100% vs. 78.3%, P = 0.049). In the ARS group, only 1 of 23 patients died (due to cancer of unknown primary origin) during the observation period (4.4%), whereas 8 of 25 non-ARS patients (32.0%) died during the observation period (6 from respiratory failure, 1 from oropharyngeal cancer, and 1 from rupture of an abdominal aortic aneurism). Both the overall death rate and the death rate from respiratory failure were significantly lower in the ARS group (P = 0.02 and P = 0.02, respectively). Kaplan—Meier survival curves are shown in Fig. 2. The 5-year and 10-year survival rates were higher in the ARS group than in the non-ARS group (5-year: 100% vs. 69.1%; 10-year: 92.3% vs. 40.8%, P = 0.02 by log-rank test).


Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.

Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, Sumikawa H, Johkoh T, Nakashima R, Imura Y, Mimori T, Suda T - PLoS ONE (2015)

Kaplan—Meier survival curves.The 5-year and 10-year survival rates were higher in the ARS group than in the non-ARS group (5-year: 100% vs. 69.1%; 10-year: 92.3% vs. 40.8%, P = 0.02 by log-rank test).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4366175&req=5

pone.0120313.g002: Kaplan—Meier survival curves.The 5-year and 10-year survival rates were higher in the ARS group than in the non-ARS group (5-year: 100% vs. 69.1%; 10-year: 92.3% vs. 40.8%, P = 0.02 by log-rank test).
Mentions: Twenty-two of 23 patients in the ARS group (95.7%) and 23 of 25 in the non-ARS group (92.0%) were treated for PM/DM-ILD during the observation period (Table 5). Although there was no statistically significant difference in the treatment regimen between the two groups (P = 0.22), ARS group patients exhibited a significantly higher response rate (100% vs. 78.3%, P = 0.049). In the ARS group, only 1 of 23 patients died (due to cancer of unknown primary origin) during the observation period (4.4%), whereas 8 of 25 non-ARS patients (32.0%) died during the observation period (6 from respiratory failure, 1 from oropharyngeal cancer, and 1 from rupture of an abdominal aortic aneurism). Both the overall death rate and the death rate from respiratory failure were significantly lower in the ARS group (P = 0.02 and P = 0.02, respectively). Kaplan—Meier survival curves are shown in Fig. 2. The 5-year and 10-year survival rates were higher in the ARS group than in the non-ARS group (5-year: 100% vs. 69.1%; 10-year: 92.3% vs. 40.8%, P = 0.02 by log-rank test).

Bottom Line: Ten-year survival rate was also significantly higher in the ARS group than in the non-ARS group (91.6% vs. 58.7%, P = 0.02).Univariate Cox hazards analysis revealed that the presence of anti-ARS antibodies was associated with better prognosis (HR = 0.34, 95% CI 0.08-0.80; P = 0.01).The presence of anti-ARS antibodies is a possible prognostic marker in patients with PM/DM-ILD.

View Article: PubMed Central - PubMed

Affiliation: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

ABSTRACT

Background: In polymyositis/dermatomyositis (PM/DM), anti-aminoacyl-tRNA synthetase (ARS) antibodies are closely associated with interstitial lung disease (ILD), a frequent pulmonary complication. However, the clinical significance of anti-ARS antibodies is not well established.

Objective: We aimed to evaluate the clinical significance of anti-ARS antibodies in PM/DM-ILD patients.

Methods: Forty-eight consecutive PM/DM-ILD patients were studied retrospectively. Anti-ARS antibodies were screened by ELISA and confirmed by RNA immunoprecipitation test. Medical records, high-resolution computed tomography images, and surgical lung biopsy specimens were compared between ARS-positive (ARS group) and ARS-negative patients (non-ARS group).

Results: Anti-ARS antibodies were detected in 23 of 48 patients (48%). Radiologically, nonspecific interstitial pneumonia (NSIP) pattern was observed more frequently in the ARS group than in the non-ARS group (73.9% vs. 40%, P = 0.02). Pathologically, NSIP was the most frequent in both groups. Ten-year survival rate was also significantly higher in the ARS group than in the non-ARS group (91.6% vs. 58.7%, P = 0.02). Univariate Cox hazards analysis revealed that the presence of anti-ARS antibodies was associated with better prognosis (HR = 0.34, 95% CI 0.08-0.80; P = 0.01).

Conclusions: The presence of anti-ARS antibodies is a possible prognostic marker in patients with PM/DM-ILD.

Show MeSH
Related in: MedlinePlus